MATRITECH INC/DE/
8-K, 1998-05-20
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: NYER MEDICAL GROUP INC, 10QSB, 1998-05-20
Next: RUSHMORE FINANCIAL GROUP INC, 10QSB, 1998-05-20



<PAGE>
 
                      SECURITIES AND EXCHANGE COMMISSION
                                        
                             WASHINGTON, D.C. 20549


                                    FORM 8-K


                                 CURRENT REPORT



                       PURSUANT TO SECTION 13 OR 15(D) OF
                      THE SECURITIES EXCHANGE ACT OF 1934
                                        

        Date of report (Date of earliest event reported):  MAY 14, 1998
                                                           ------------
                                        

                                MATRITECH, INC.
         ------------------------------------------------------------
            (Exact Name of Registrant as Specified in Its Charter)


                                   Delaware
                   -----------------------------------------
                (State or Other Jurisdiction of Incorporation)

               0-12128                                  04-2985132
               -------                                  ----------
       (Commission File Number)             (IRS Employer Identification No.)


        330 Nevada Street, Newton, Massachusetts       02416  USA
       ----------------------------------------------------------------
       (Address of Principal Executive Offices)        (Zip Code)


              Registrant's telephone number, including area code:


                                 (617) 928-0820
                                 --------------
                                        
                                        


                               Page 1 of 3 Pages
<PAGE>
 
ITEM 5.  OTHER EVENTS.

     U.S. Food and Drug Administration Response to 510(k) Submission
     ---------------------------------------------------------------

     Matritech, Inc. (the "Company") received a determination from the U.S. Food
and Drug Administration ("FDA") that its NuMA(TM) Test Kit for colon cancer did
not meet the criteria for 510(k) marketing clearance. The Company is continuing
its discussions with the FDA regarding clearance for this product and is also
continuing with ongoing studies necessary for a premarket approval application
("PMA").

     RESIGNATION OF VICE PRESIDENT, FINANCE
     --------------------------------------

     The Company announced that Leslie R. Teso, Vice President, Finance,
Secretary and Treasurer will be leaving the Company to pursue other career
interests. Martin Zelbow has been appointed Acting Vice President, Finance while
the Company conducts a search for a suitable replacement.


                               Page 2 of 3 Pages
<PAGE>
 
                                   SIGNATURES
                                        

                                        
     Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.



                                        MATRITECH, INC.


May 20, 1998                            By:    /s/ Stephen D. Chubb
                                           ---------------------------------
                                           Name:   Stephen D. Chubb
                                           Title:  Chairman, Director and
                                                   Chief Executive Officer


                               Page 3 of 3 Pages


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission